Boehringer Ingelheim sales and marketing update

Boehringer Ingelheim launched 150 mg Pradaxa dabigatran in the U.S to prevent stroke and blood clots in patients with abnormal heart rhythm (atrial fibrillation). The company said the 75 mg dose of t...